Strengthening platform capabilities… accelerating product development
Adaptimmune is always looking for the right technology partnerships to help develop and deliver new therapies for people living with cancer. The company has alliances with a range of partners listed below.
Alpine Immune Sciences
Adaptimmune has a collaboration and license agreement with Alpine Immune Sciences, Inc., to develop next-generation SPEAR T-cell products.
Cell and Gene Therapy Catapult
Our agreement with Cell and Gene Therapy Catapult enables us to have our own dedicated GMP (Good Manufacturing Practices) vector manufacturing space in the UK.
Center for Cancer Immune Therapy
We signed a collaboration agreement with the Center for Cancer Immune Therapy (CCIT-DK - based in Copenhagen) in 2020. CCIT is one of the leading academic centers in Europe involved in researching tumor infiltrating lymphocyte (TIL) therapies.
Galapagos
On May 30, 2024, Adaptimmune entered into a clinical collaboration and exclusive option and license agreement with Galapagos to evaluate Adaptimmune’s next-generation TCR T-cell therapy (uza-cel) in a proof-of-concept clinical trial in head & neck cancer patients, using T-cells manufactured with Galapagos’ decentralized cell manufacturing platform. Following completion of the proof-of-concept trial, Galapagos has an exclusive option to license global rights to uza-cel in head & neck cancer and potential future solid tumor indications.
Initial in vitro results suggest that uza-cel, produced on Galapagos’ innovative manufacturing platform, yields early phenotype T-cells that could improve efficacy and durability, while also enabling the delivery of T-cells with a vein-to-vein time of seven days in a patient population in which rapid access to treatment is vital.
Genentech
Adaptimmune entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group, to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.
MD Anderson Cancer Center
Adaptimmune has engaged with The University of Texas MD Anderson Cancer Center since 2016 to expedite the development of novel adaptive T-cell therapies for multiple types of cancer.
Noile-Immune Biotech
Adaptimmune is working with Noile-Immune Biotech Inc. to co-develop next‑generation SPEAR T-cell products, incorporating Noile-Immune’s PRIME (PRoliferation Inducing and Migration Enhancing) technology.